These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 9042615

  • 1. Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors.
    Newman-Tancredi A, Audinot-Bouchez V, Gobert A, Millan MJ.
    Eur J Pharmacol; 1997 Jan 29; 319(2-3):379-83. PubMed ID: 9042615
    [Abstract] [Full Text] [Related]

  • 2. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ.
    J Pharmacol Exp Ther; 1997 Jul 29; 282(1):181-91. PubMed ID: 9223553
    [Abstract] [Full Text] [Related]

  • 3. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL.
    J Pharmacol Exp Ther; 1998 Oct 29; 287(1):167-86. PubMed ID: 9765336
    [Abstract] [Full Text] [Related]

  • 4. [35S]GTPgammaS binding at the human dopamine D4 receptor variants hD4.2, hD4.4 and hD4.7 following stimulation by dopamine, epinephrine and norepinephrine.
    Czermak C, Lehofer M, Liebmann PM, Traynor J.
    Eur J Pharmacol; 2006 Feb 15; 531(1-3):20-4. PubMed ID: 16423344
    [Abstract] [Full Text] [Related]

  • 5. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
    Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, Marwood R, Mcallister G, Myers J, Curtis N, Kulagowski JJ, Leeson PD, Ridgill M, Graham M, Matheson S, Rathbone D, Watt AP, Bristow LJ, Rupniak NM, Baskin E, Lynch JJ, Ragan CI.
    J Pharmacol Exp Ther; 1997 Nov 15; 283(2):636-47. PubMed ID: 9353380
    [Abstract] [Full Text] [Related]

  • 6. Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
    Newman-Tancredi A, Cussac D, Audinot V, Millan MJ.
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun 15; 359(6):447-53. PubMed ID: 10431754
    [Abstract] [Full Text] [Related]

  • 7. Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor.
    Lanau F, Zenner MT, Civelli O, Hartman DS.
    J Neurochem; 1997 Feb 15; 68(2):804-12. PubMed ID: 9003072
    [Abstract] [Full Text] [Related]

  • 8. Characterization of dopaminergic compounds at hD2short, hD4.2 and hD4.7 receptors in agonist-stimulated [35S]GTPgammaS binding assays.
    Gilliland SL, Alper RH.
    Naunyn Schmiedebergs Arch Pharmacol; 2000 May 15; 361(5):498-504. PubMed ID: 10832603
    [Abstract] [Full Text] [Related]

  • 9. Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors.
    Roberts DJ, Lin H, Strange PG.
    Biochem Pharmacol; 2004 May 01; 67(9):1657-65. PubMed ID: 15081865
    [Abstract] [Full Text] [Related]

  • 10. Characterization of a novel iodinated ligand, IPMPP, for human dopamine D4 receptors expressed in CHO cells.
    Kung MP, Stevenson DA, Zhuang ZP, Vessotskie JM, Chumpradit S, Sun XM, Kung HF.
    Life Sci; 1997 May 01; 60(2):91-100. PubMed ID: 9000114
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the functional activity of dopamine ligands at human recombinant dopamine D4 receptors.
    Chabert C, Cavegn C, Bernard A, Mills A.
    J Neurochem; 1994 Jul 01; 63(1):62-5. PubMed ID: 7911513
    [Abstract] [Full Text] [Related]

  • 12. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
    Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Bruinvels AT, Geisse S, Sommer B, Hoyer D, Tricklebank M, Schoeffter P.
    Br J Pharmacol; 1998 Jul 01; 124(5):889-96. PubMed ID: 9692773
    [Abstract] [Full Text] [Related]

  • 13. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A.
    Eur J Pharmacol; 2006 Mar 27; 535(1-3):135-44. PubMed ID: 16554049
    [Abstract] [Full Text] [Related]

  • 14. Cloning, expression, functional coupling and pharmacological characterization of the rat dopamine D4 receptor.
    Gazi L, Schoeffter P, Nunn C, Croskery K, Hoyer D, Feuerbach D.
    Naunyn Schmiedebergs Arch Pharmacol; 2000 May 27; 361(5):555-64. PubMed ID: 10832611
    [Abstract] [Full Text] [Related]

  • 15. Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding.
    Malmberg, Mikaels, Mohell N.
    J Pharmacol Exp Ther; 1998 Apr 27; 285(1):119-26. PubMed ID: 9536001
    [Abstract] [Full Text] [Related]

  • 16. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
    Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G, Popiolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH.
    Eur J Pharmacol; 2006 Dec 15; 552(1-3):36-45. PubMed ID: 17056032
    [Abstract] [Full Text] [Related]

  • 17. Serotonergic agonists behave as partial agonists at the dopamine D2 receptor.
    Rinken A, Ferré S, Terasmaa A, Owman C, Fuxe K.
    Neuroreport; 1999 Feb 25; 10(3):493-5. PubMed ID: 10208577
    [Abstract] [Full Text] [Related]

  • 18. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ, Cussac D, Gobert A, Lejeune F, Rivet JM, Mannoury La Cour C, Newman-Tancredi A, Peglion JL.
    J Pharmacol Exp Ther; 2004 Jun 25; 309(3):903-20. PubMed ID: 14978194
    [Abstract] [Full Text] [Related]

  • 19. D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia.
    Sharma A, Kramer ML, Wick PF, Liu D, Chari S, Shim S, Tan W, Ouellette D, Nagata M, DuRand CJ, Kotb M, Deth RC.
    Mol Psychiatry; 1999 May 25; 4(3):235-46. PubMed ID: 10395213
    [Abstract] [Full Text] [Related]

  • 20. Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells.
    Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Langenegger D, Sommer B, Hoyer D, Tricklebank M, Schoeffter P.
    Br J Pharmacol; 1999 Oct 25; 128(3):613-20. PubMed ID: 10516640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.